Protein Build-up Leads to Neurons Misfiring
News Jul 20, 2012
The findings — the first recorded in vivo using a transgenic mouse model of Parkinson's disease — are published in today's (July 18) issue of the Journal of Neuroscience and provide new insights into how Parkinson's disease and other neurodegenerative disorders known as synucleinopathies work and progress at the cellular level.
Previous in vitro studies using cell cultures had suggested abnormal accumulation of alpha-synuclein dysregulated intracellular handling and movement of calcium, which is used as a signaling molecule and neurotransmitter. It was unclear, however, whether calcium alterations occurred in more complex, living animals.
"This is the first time we've been able to verify the role of alpha-synuclein aggregates in vivo," said senior author Eliezer Masliah, M.D., professor of neurosciences and pathology.
"The aggregates affect the cell membrane of neurons, making them more porous. They also affect the membranes of organelles inside neurons, such as the mitochondria that are part of the cell's machinery for generating energy. Energy is necessary to pump calcium in and out of the cell. If mitochondria membranes are compromised, calcium accumulates, further damaging the neuron and causing it to misfire."
Masliah said the new revelations, made using imaging technologies developed by first author Anna Devor, Ph.D., associate adjunct professor of neuroscience, may help scientists and doctors quantify and repair neuronal damage caused by alpha-synuclein accumulation.
"We have already started to utilize this discovery as a bio-marker and reporter of neuronal damage," said Masliah. "We have compounds developed in collaboration with others to ‘plug' the holes in the neurons and mitochondria and prevent the abnormal calcium currents. We can monitor in real-time in live animals how our drugs revert the toxic effects of alpha-synuclein. This represents a unique and fast strategy to evaluate novel compounds."
Co-authors are Lidia Reznichenko, Qun Cheng, Krystal Nizar, Payam A. Saisan, Edward M. Rockenstein, Tanya Gonzalez, Christina Patrick, Brian Spencer and Paula Desplats, Department of Neurosciences, UC San Diego; Sergey L. Gratiy, Department of Radiology, UC San Diego; Anders M. Dale, departments of Neurosciences and Radiology, UC San Diego; Anna Devor, departments of Neurosciences and Radiology, UC San Diego; and Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School.
Funding for this research came, in part, from the National Institute on Aging (grant AG-02270), The National Institute of Neurological Disorders and Stroke (grants NS-051188, NS-057198 and NS-0507096), the National Institute of Biomedical Imaging and Bioengineering (grants EB-009118 and EB-000790) and the Short Family Fund.
New Automated Screening Method for Identifying Drug CandidatesNews
Scientists at DESY have developed a new method that enables automated and fast screening of promising drug candidates.READ MORE
Progressive Kidney Disease: New Compound Restores Kidney FunctionNews
A team led by researchers describe a new approach to prevent death in these essential kidney cells. Studying multiple animal models of kidney disease, the team discovered a compound that can impede loss of the filtration cells and restore kidney function.READ MORE
3D Mini Brains Accelerate Drug Screening and Brain Function ResearchNews
Houston Methodist neuroscientist Robert Krencik, Ph.D., and his team have developed a new system to reduce the time it takes to grow these brain models, which will give them the ability to screen drugs and study what’s behind disease-causing mutations more quickly.READ MORE